Inactive Instrument

News Vital Therapies Inc Nasdaq

Equities

US92847R1041

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Immunic to Participate in Investor and Scientific Conferences in May	May. 06	PR
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal	May. 01	AQ
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation	May. 01	AQ
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update	May. 01	PR
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation	Apr. 30	CI
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role	Apr. 29	AQ
Transcript : Immunic, Inc. - Special Call	Apr. 09
Immunic to Host MS R&D Day and Participate in Investor Conferences in April	Apr. 04	PR
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	Mar. 21	MT
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month	Mar. 21	AQ
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy	Mar. 21	AQ
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States	Mar. 20	PR
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024	Mar. 08	AQ
Immunic to Participate in Investor and Scientific Conferences in March	Mar. 07	PR
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024	Feb. 29	PR
Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating	Feb. 23	MT
Immunic reports successful 2023 and prepares for key 2025 milestones	Feb. 22	AQ
Transcript : Immunic, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update	Feb. 22	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vital Therapies Inc Nasdaq

Equities

US92847R1041

Summary

Filters